Eli Lilly and Co (LLY.NO)
34.30
+0.44
(+1.30%)
CAD |
NEO |
Sep 19, 15:58
Price Chart
Key Stats
Price and Performance | |
---|---|
Market Cap | 1.132T |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | -- |
Valuation | |
PE Ratio | 113.84 |
PE Ratio (Forward) | Upgrade |
PS Ratio | 21.52 |
Price to Book Value | 60.97 |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | 0.0480 |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | 2.130 |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | -- |
Profile
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology. |
URL | https://www.lilly.com |
Investor Relations URL | https://investor.lilly.com/ |
HQ State/Province | Indiana |
Sector | |
Industry | |
Equity Style | Large Cap/Growth |
Next Earnings Release | Oct. 30, 2024 |
Last Earnings Release | Aug. 08, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | Aug. 15, 2024 |
Ratings
Profile
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology. |
URL | https://www.lilly.com |
Investor Relations URL | https://investor.lilly.com/ |
HQ State/Province | Indiana |
Sector | |
Industry | |
Equity Style | Large Cap/Growth |
Next Earnings Release | Oct. 30, 2024 |
Last Earnings Release | Aug. 08, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | Aug. 15, 2024 |